A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice |
| |
| Affiliation: | 1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen 361102, China;2. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, China;3. Beijing Wantai Biological Pharmacy Enterprise, Beijing 102206, China;4. Department of Microbiology and Molecular Genetics, New Jersey Medical School, Rutgers University, 225 Warren Street, Newark, NJ 070101, USA;1. USC Norris Comprehensive Cancer Ctr. Molecular and Computational Biology Program, Department of Biological Sciences, Departments of Pathology, Biochemistry & Molecular Biology, Molecular Microbiology & Immunology, Urology, University of Southern California Keck School of Medicine, 1441 Eastlake Ave., Rm, 5428, Los Angeles, CA 90089-9176, United States;2. Department of Physiology and Pharmacology, State University of New York Downstate Medical Center, New York, NY 11203, United States;3. Department of Microbiology and Molecular Genetics, Michigan State University, 5175 Biomedical Physical Sciences, East Lansing, MI 48824, United States;1. Department of Pediatrics, Konan Kosei Hospital, Konan, Aichi, Japan;2. Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan;1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian 361005, PR China;2. School of Public Health, Xiamen University, Xiamen, Fujian 361005, PR China;3. School of Life Science, Xiamen University, Xiamen, Fujian 361005, PR China;4. Xiamen Innovax Biotech Co., Ltd, Xiamen, Fujian 361005, PR China;1. Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands;2. Janssen Research & Development, Beerse, Belgium;3. Crucell Vaccine Institute, Janssen Center of Excellence for Immunoprophylaxis, Leiden, The Netherlands |
| |
| Abstract: | Varicella-zoster virus (VZV) is a highly infectious agent of varicella and herpes zoster (HZ). Vaccination is by far the most effective way to prevent these diseases. More safe, stable and efficient vaccines, such as epitope-based vaccines, now have been increasingly investigated by many researchers. However, only a few VZV neutralizing epitopes have been identified to date. We have previously identified a linear epitope between amino acid residues 121 and 135 of gE. In this study, we validated that this epitope is highly conserved amongst different VZV strains that covered five existing phylogenetic clades with an identity of 100%. We evaluated the immunogenicity of the recombinant hepatitis B virus core (HBc) virus-like particles (VLPs) which included amino acids (121–135). VZV-gE-specific antibodies were detected in immunized mouse serum using ELISA. The anti-peptide antiserum positively detected VZV via Western blot and immunofluorescent staining assays. More importantly, these peptides could neutralize VZV, indicating that these peptides represented neutralizing epitopes. These findings have important implications for the development of epitope-based protective VZV vaccines. |
| |
| Keywords: | Varicella-zoster virus Neutralizing linear epitope Epitope vaccine Glycoprotein E |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
